

 Early Warning System

EIB-20250158

SOUTHERN NEIGHBOURHOOD ALTA SEMPER FUND II



Quick Facts

Countries	Egypt, Morocco
Financial Institutions	European Investment Bank (EIB)
Status	Proposed
Bank Risk Rating	U
Borrower	ALTA SEMPER GROWTH II GP (Alta Semper Capital LLP)
Sectors	Education and Health, Finance, Industry and Trade
Investment Type(s)	Equity
Investment Amount (USD)	\$ 30.00 million
Project Cost (USD)	\$ 150.00 million



Project Description

According to the EIB, the project supports the growth of local pharmaceutical and healthcare companies in the Southern Neighbourhood and, to a lesser extent, in Sub-Saharan Africa, through participation in a private equity fund that invests to enhance affordable access to quality disruptive technology and medical services. The project is expected to be strongly aligned with EU trade interests with many portfolio companies that are either expected to source equipment from EU-based suppliers or partner with EU pharmaceutical and MedTech companies to provide regional services.

The project supports the growth of local companies and enhances affordable access to quality healthcare products and medical services for final beneficiaries, through investments that will contribute to fulfilling the financing gap of growth capital for pharmaceutical and healthcare companies, predominantly in Northern Africa (Egypt and Morocco), and to a lower extent in Sub-Saharan Africa.

This project is not only aligned with the EU-Africa Global Gateway Investment Package, reinforcing the EU's world-leading position as an innovative trade powerhouse in the life sciences and healthcare sector, but also aims to contribute to the 2030 ambition set by the EU under the EU Global Health Strategy and the EU-Africa Global Gateway Investment Package, to strengthen African pharmaceutical systems with regional manufacturing capacities to meet local needs and demand, by promoting research and cross-border innovation in healthcare.

The project will support local healthcare system strengthening through private-sector investments into the equitable access to specialised clinical care. The project is expected to contribute to Northern Africa's inclusive economic growth, sustainable and resilient human development, whilst also encouraging the development of the healthcare sector and vital job creation in Northern and Sub-Saharan Africa.



Investment Description

- European Investment Bank (EIB)

Financial Intermediary

Financial Intermediary: A commercial bank or financial institution that receives funds from a development bank. A financial intermediary then lends these funds to their clients (private actors) in the form of loans, bonds, guarantees and equity shares. Financial intermediaries include insurance, pension and equity funds. The direct financial relationship is between the development bank and the financial intermediary.

- [Alta Semper Capital](#) (Financial Intermediary)



Private Actors Description

As stated by Bloomberg, Alta Semper Capital LLP operates as a private equity firm. The Company invests in consumer and healthcare companies. Alta Semper Capital serves clients in the United Kingdom.

As stated on the company's website, Alta Semper Capital is a private equity manager founded by Ronald Lauder, (Chairman of Clinique Laboratories, a subsidiary of the Estée Lauder Company, and a former US ambassador to Austria), Richard Parsons (Chairman of Rockefeller Foundation, former Chairman of Citigroup and Chairman/CEO of Time Warner Group) and Afsane Jetha.



Contact Information

No project contacts provided at the time of disclosure.

Financial Intermediary - Alta Semper Capital LLP:

Address: First Floor, 35 Berkeley Square, London W1J 5BF, United Kingdom

Phone: +207 100 0670

Email: info@altasemper.com

Website: <https://www.altasemper.com/>

ACCESS TO INFORMATION

You can submit an information request for project information at: <https://www.eib.org/en/infocentre/registers/request-form/request-form-default.htm>

ACCOUNTABILITY MECHANISM OF EIB

The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address: complaints@eib.org, by completing the online complaint form available at the following address: <http://www.eib.org/complaints/form> via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check: http://www.eib.org/attachments/strategies/complaints_mechanism_policy_en.pdf

When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at: <http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces>



Other Related Projects

- IFC-47700 Alta Semper II